Bavarian Nordic has signed a manufacturing agreement with SII, expanding its strategic partnership through a contract for its ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

Vima's selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.

Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin to treat peritumoral brain oedema in Japan.

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation of Wegovy.